Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
Dutch Initiative on Crohn and Colitis, Vince B. C. Biemans, C. Janneke van der Woude, Gerard Dijkstra, Andrea E. van der Meulen-de Jong, Mark Lowenberg, Nanne K. de Boer, Bas Oldenburg, Nidhi Srivastava, Jeroen M. Jansen, Alexander G. L. Bodelier, Rachel L. West, Annemarie C. de Vries, Jeoffrey J. L. Haans, Dirk de Jong, Frank Hoentjen, Marieke J. Pierik*
Research output: Contribution to journal › Article › Academic › peer-review
120Citations
(Scopus)
254Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment'. Together they form a unique fingerprint.